All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Camila Morrone in ...

The University of Houston System's general counsel defended the dual course reviews underway across UH campuses on Thursday, telling the Board of Regents that top administrators chose an approach that ...

Blake has over a decade of experience writing for the web, with a focus on mobile phones, where he covered the smartphone boom of the 2010s and the broader tech scene. When he's not in front of a ...

Bottom Line: Why Choose UWorld? After spending time inside the platform, UWorld feels the most dialed in for serious ACT repetition and mistake analysis. It keeps everything centered on practice ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Four months after ...

The 2026 Mazda CX-50 reminds me of T.S. Eliot’s poem “Burnt Norton”: “What might have been and what has been/Point to one end, which is always present.” Because I’m classy. Introduced for model-year ...

The Dell XPS 14 brings the company’s flagship laptop back into competition with speedy Intel Core Series 3 chips and a redesign that’s more practical, yet still premium. In 2022, Dell took a big swing ...

The Food and Drug Administration reversed an earlier decision to not review Moderna's flu vaccine and will evaluate the company's modified application for a potential approval, Moderna said on Feb. 18 ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu ...

Moderna said Wednesday the Food and Drug Administration changed course and will review an amended application for its new flu vaccine, a week after rejecting the original submission and fueling ...

The Food and Drug Administration will review Moderna’s new flu vaccine after initially refusing to review the candidate, the Cambridge biotech announced early Wednesday. The FDA’s decision not to ...